Catalyst Oncology

We can’t say we recall many instances of health insurers making a big show about what they’ll pay for twice. But Aetna put out an announcement today that says if there’s uncertainty about the accuracy of a test that breast-cancer patients get, the insurer will cover a do-over. The test determines whether a patient’s tumor expresses an excess amount of a protein called HER2. If the test comes back positive, the patient may be a candidate for Genentech’s breast-cancer drug Herceptin, which targe

Go here to read the rest:
Aetna Pushes Do-Overs for Breast Cancer Test